Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Valued to Reach USD $16.23 Billion by 2030 at 7.6% CAGR

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

How Strong Is the Market Growth Outlook for the Vascular Endothelial Growth Factor (VEGF) Inhibitor Market?
The vascular endothelial growth factor (vegf) inhibitor market size has grown strongly in recent years. It will grow from $11.3 billion in 2025 to $12.11 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising incidence of cancer and retinal disorders, limited treatment options before monoclonal antibodies, growing awareness of anti-angiogenic therapy benefits, increasing physician adoption of targeted therapies, regulatory approvals of first-generation vegf inhibitors.

The vascular endothelial growth factor (vegf) inhibitor market size is expected to see strong growth in the next few years. It will grow to $16.23 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to development of next-generation vegf inhibitors, expansion in immuno-oncology combinations, increasing adoption of personalized medicine, rising investments in ophthalmic drug development, integration of digital monitoring and AI-based treatment assessment. Major trends in the forecast period include rising adoption of vegf inhibitors in oncology and ophthalmology, increasing development of monoclonal antibodies and anti-angiogenic therapies, growth in intravitreal and intravenous administration routes, expansion of personalized medicine and targeted therapy approaches, increasing clinical trials and research for novel vegf inhibitors.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report

Which Major Growth Drivers Will Influence the Vascular Endothelial Growth Factor (VEGF) Inhibitor Market by 2030?
The growing prevalence of cancer and macular degeneration is expected to propel the growth of the VEGF inhibitor market going forward. Cancer is a disease in which abnormal cells grow uncontrollably, potentially spreading to other parts of the body, while macular degeneration is a medical condition that leads to deterioration of the central portion of the retina, affecting vision. The rise in prevalence of these conditions is fueled by factors such as an aging population and lifestyle-related risks, leading to increased demand for effective treatments and healthcare solutions. Vascular endothelial growth factor (VEGF) Inhibitors help combat cancer by blocking the formation of new blood vessels that tumors need to grow and spread, thereby restricting tumor growth and metastasis. For instance, February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the growing prevalence of cancer and macular degeneration is driving the growth of the VEGF inhibitor market.

What Are the Main Segments of the Vascular Endothelial Growth Factor (VEGF) Inhibitor Market?
The vascular endothelial growth factor (vegf) inhibitor market covered in this report is segmented –

1) By Drugs Type: Avastin, Tecentriq, Lucentis, Cometriq, Eylea, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Intravitreal
3) By Application: Oncology, Ophthalmology, Other Applications

Subsegments:
1) By Avastin: Oncology Applications, Ophthalmology Applications
2) By Tecentriq: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Bladder Cancer, Triple-Negative Breast Cancer
3) By Lucentis: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Retinal Vein Occlusion
4) By Cometriq: Medullary Thyroid Cancer, Renal Cell Carcinoma
5) By Eylea: Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
6) By Other Drug Types: Immuno-Oncology Drugs, Anti-Angiogenic Agents, Other Monoclonal Antibodies

Which Trends Are Most Likely to Influence Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Growth in the Next Decade?
Major companies operating in the VEGF inhibitor market are focusing on developing innovative ophthalmic treatments, such as higher-concentration intravitreal injection solutions to extend dosing intervals and reduce treatment burden for patients. Higher-concentration intravitreal injection solutions are eye medications with an increased amount of active drug per dose, helping reduce the frequency of injections while maintaining effectiveness and easing the treatment burden for patients. For instance, in April 2024, Santen Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, in a partnership with Bayer Yakuhin, a Japan-based pharmaceutical and life sciences company, launched the Ophthalmic VEGF Inhibitor Eylea 8mg Solution for Intravitreal Injection 114.3 mg/mL. These are standard treatments for conditions such as age-related macular degeneration (nAMD) and diabetic macular edema (DME), which can lead to blindness. Eylea 8mg, with a higher concentration than its predecessor, offers an extended dosing interval of up to 16 weeks, reducing the frequency of intravitreal injections while maintaining efficacy and safety. This advancement aims to lessen the treatment burden on patients and set a new standard of care. It is a strategic partnership aimed at expanding the reach and availability of this innovative ophthalmic treatment.

Which Players Dominate the Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Landscape?
Major companies operating in the vascular endothelial growth factor (vegf) inhibitor market are F. Hoffmann-La Roche AG, Bayer AG, Regeneron Pharmaceuticals Inc., AstraZeneca Plc., Novartis AG, Pfizer Inc., Eli Lilly and Company, Exelixis Inc., Amgen Inc., Sanofi S.A., Cipla Limited, Biocon, Dr. Reddy's Laboratories, Innovent Biologics, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Ipsen, Oxurion, Pharmstandard Group, Zentiva, Coherus BioSciences Inc., AVEO pharmaceuticals, Eisai Co. Ltd.

Get the full vascular endothelial growth factor (vegf) inhibitor market report here:
https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report

Which region represents the fastest-growing market for the Vascular Endothelial Growth Factor (VEGF) Inhibitor Market?
North America was the largest region in the vascular endothelial growth factor (VEGF) inhibitor market in 2025. Middle East is expected to be the fastest-growing region in the vascular endothelial growth factor (VEGF) inhibitor market share during the forecast period. The regions covered in the vascular endothelial growth factor (vegf) inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company